Related Experiment Videos

[Effects of carvedilol on the hemodynamics and its tolerance in elderly patients]

Toshinobu Asai1, Masafumi Kuzuya, Akihiko Koike

  • 1Department of Geriatrics, Nagoya University Graduate School of Medicine.

Insights

Carvedilol, an alpha-beta blocker, safely improved cardiac function and lowered blood pressure in elderly patients with hypertension or angina. This study highlights its potential benefits for older individuals with cardiovascular conditions.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Beta-blockers offer benefits in chronic heart failure but pose side effect risks, leading to physician hesitancy in elderly patients.
  • Carvedilol is a non-selective beta-blocker with alpha-1 blocking vasodilating effects, differentiating it from traditional beta-blockers.

Purpose of the Study:

  • To evaluate the effects of carvedilol on cardiac parameters in elderly Japanese patients with hypertension, angina pectoris, or both.
  • To determine if carvedilol can safely improve left ventricular function in this demographic.

Main Methods:

  • A 12-week study involving 16 elderly patients (age ≥ 65) with hypertension, angina, or both.
  • Oral administration of carvedilol (10-20 mg daily) followed by echocardiography and hemodynamic parameter calculation.

Main Results:

  • Significant reduction in systolic and diastolic blood pressure (p < 0.001/p < 0.01).
  • Increase in ejection fraction (p < 0.05) and decrease in heart rate (p < 0.05).
  • Carvedilol demonstrated a safe profile in improving cardiac function and blood pressure.

Conclusions:

  • Carvedilol effectively and safely improved ejection fraction and decreased blood pressure in elderly patients with hypertension and/or angina.
  • Alpha-beta blockers like carvedilol may offer significant benefits for elderly patients when considering individual health conditions.

Related Concept Videos

Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Antagonists: &#593; and &#946;-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...